Selected ongoing studies using checkpoint blockade immunotherapy in definitive treatment of locally advanced cervical cancer
| NCT identifier | Title | Phase | Planned enrollment | Primary endpoint(s) |
| NCT03830866 | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) | III | 770 | Progression-free survival |
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | III | 980 | Progression-free and overall survival |
| NCT03612791 | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) | II | 189 | Progression-free survival |
| NCT02635360 | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | II | 88 | Change in immunologic markers |
| NCT03833479 | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemoradiation (ATOMICC) | II | 132 | Progression-free survival |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node-Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | I | 40 | Clonal expansion of T-cell receptors |
| NCT03298893 | Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL) | I | 21 | Dose-limiting toxicity |